Dupixent Cancer Lawsuit (Update May, 2026)
Welcome to the update by a Nashville Dupixent Cancer Lawyer on the Dupixent Cancer Lawsuit.
Current Litigation Status
- Individual Lawsuits: Plaintiffs across the U.S. are currently filing individual product liability and wrongful death claims.
- MDL Motion Pending: In February 2026, a motion was filed to transfer and consolidate related federal cases into a Multidistrict Litigation (MDL) in the Northern District of Georgia.
- No Settlements or Verdicts: There have been no jury verdicts or publicly disclosed settlements to date.
- No Class Action: There is currently no active class action lawsuit; legal experts expect most cases to proceed as an MDL.
Key Allegations and Evidence
- Failure to Warn: Lawsuits claim the manufacturers knew or should have known about the lymphoma risk from post-marketing data and clinical studies but did not update the drug’s label.
- Scientific Research: A 2024 study published in Dermatologic Therapy found that patients treated with Dupixent were more than four times as likely to develop CTCL compared to those who never received the drug.
- FDA Action: In March 2025, the FDA issued a Newly Identified Safety Signal (NISS) and launched a formal investigation after receiving hundreds of adverse event reports regarding CTCL and other lymphomas in Dupixent users.
Eligibility and Filing
- Qualification: Generally, individuals may qualify if they used Dupixent for at least one month and were subsequently diagnosed with CTCL or its subtypes, such as mycosis fungoides or Sézary syndrome.
- Time Limits: Deadlines to file (statutes of limitation) vary by state, typically ranging from one to three years from the date of diagnosis or discovery of the harm.
What Is Dupixent?
- Dupixent (dupilumab): Is an injectable biologic medication that is used to treat particular types of inflammatory diseases.
- Mechanism of Action: It works by treating the underlying cause of inflammation and is commonly prescribed for people with atopic dermatitis, eczema, asthma, chronic sinusitis, and eosinophilic esophagitis.
- Recent studies on Dupixent and Cancer: Have shown that Dupixent use may increase the risk of certain types of cancers known as Cutaneous T-cell Lymphomas (CTCL), including its subtypes Mycosis fungoides and Sezary syndrome, by as much as 300% or more in people who used the medication.
- Potential Compensation: People who used Dupixent and were later diagnosed with CTCL may be eligible to file a Dupixent Cancer Lawsuit and potential entitled to substantial compensation. If you suffered Dupixent and Cancer call Nashville Dupixent Cancer Lawyer Timothy L. Miles today for a free case evaluation. (855)-846-6529 or [email protected].
Serious Dupixent Side Effects
Serious Dupixent Side Effects: The medication can cause serious side effects, including:
- Allergic reactions. Dupixent can cause allergic reactions, including skin reactions, that can sometimes be severe. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing, swelling of the face, lips, mouth, tongue or throat, fainting, dizziness, feeling lightheaded, fast pulse, fever, hives, skin rash, including rash that looks like a bullseye or painful red or blue bumps under the skin, general ill feeling, itching, swollen lymph nodes, nausea or vomiting, joint pain, or cramps in your stomach area.
- Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. Your healthcare provider may send you to an ophthalmologist for an exam if needed.
- Joint aches and pain. Some people who use Dupixent have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. Tell your healthcare provider about any new or worsening joint symptoms. Your healthcare provider may stop Dupixent if you develop joint symptoms.
Dupixent and Cancer
- Dupixent and its Intended Use: Dupixent is a prescription injection manufactured by Sanofi and Regeneron and first approved by the FDA in 2017. It is commonly prescribed for patients with:
-
- Moderate-to-severe eczema (atopic dermatitis)
- Asthma
- Cchronic sinusitis with nasal polyps
- eosinophilic esophagitis
- Dupixent And Cancer: In recent years, however, Dupixent® has been linked to cutaneous T-cell lymphoma (CTCL), a rare and serious form of non-Hodgkin lymphoma. Studies published in 2024 and 2025 suggest that Dupixent® patients may face a 300% higher risk of developing CTCL yet manufacturers never warned healthcare providers or patients about this risk.
- Contact a Dupixent Cancer Lawyer: If you took Dupixent and subsequently developed CTCL or other serious Dupixent side effects or just have general questions, call Dupixent Cancer Lawyer Timothy L. Miles today, free of charge, for a free case evaluation as you may be eligible for a Dupixent Cancer Lawsuit and possibly entitled to substantial compensation. (855) 846-6529 or [email protected].
Symptoms of CTCL
Symptoms of CTCL may include:
- Itching
- Red, scaly, or thickened patches of skin
- Peeling skin
- Discolored skin
- Raised bumps or nodules
- Skin sores or ulcers
- Hair loss
- Enlarged lymph nodes
Research and the Link Between Dupixent and Cancer
Several medical reports and studies including the Nation Library of Medicine have suggested that Dupixent may be tied to an increased risk of CTCL.
-
- A study published on April 6, 2024 (Hasan et al., 2024), looked at whether people with atopic dermatitis (AD) who were treated with the drug dupilumab had a higher risk of developing cutaneous T-cell lymphoma (CTCL) compared to those who didn’t take the drug. In their first model, which adjusted for age only, they found that people who took dupilumab had a 300% higher risk of getting CTCL compared to those who didn’t (OR 4.10). Even after they adjusted for more factors—like sex, ethnicity, and race, and removed people who had taken certain other immune-suppressing drugs—the risk was still more than two times higher (OR 3.20).
-
- A second study using TriNetX data (Mandel et al., 2024) was published in August 2024 and followed a method similar to the first study by Hasan et al. The researchers excluded patients who had other inflammatory diseases or had taken biologic drugs that might be linked to lymphoma.After matching patients by age, race, and sex, they found that people with atopic dermatitis (AD) who were treated with dupilumab had a 350% higher risk of developing cutaneous T-cell lymphoma (CTCL) compared to those who weren’t treated with the drug (RR 4.59).
-
- In September 2025, a study led by Sheng-Kai Ma and his team looked at the patients in the United States with asthma who initiated dupilumab or the active comparator (combination therapy with inhaled corticosteroids (ICS) plus long-acting β-agonists (LABA), or ICS/LABA), between 2018 and 2024. After propensity score matching, dupilumab-treated patients were found to have a higher risk of lymphoma (54 versus 43 cases, hazard ratio (HR) 1.79, 95% CI 1.19-2.71), especially T-cell and natural killer (NK)-cell lymphomas (19 versus ≤10 cases, HR 4.58, 95% CI 1.82-11.53).
After adjusting for things like age, gender, income, other health problems, and medicine use, the risk of CTCL was more than 4.5 times higher in the dupilumab group. Dupilumab was also linked to an overall increased risk of any type of lymphoma. When the researchers looked only at patients who had taken their medications for at least 16 weeks, the risk numbers went up even more, especially for combined mature T and NK cell lymphomas, a broader group of cancers including CTCL and other subtypes, which was over 14 times higher for dupilumab users.
- Acceleration of cutaneous T-cell lymphoma following dupilumab administration
-
- A 2019 study published in the Nation Library of Medicine, Acceleration of cutaneous T-cell lymphoma following dupilumab administration, showed multiple patients saw CTCL symptoms accelerate while using dupilumab.
-
- Case reports warning that Dupixent may “unmask” or worsen hidden lymphomas mistaken for eczema
These findings have pushed doctors to re-evaluate how and when to prescribe Dupixent — especially when patients show unusual skin reactions that don’t improve.
Patient Reports of Cancer Linked to Dupixent
- Patient and Healthcare Reports on FAERS: In addition to the clinical research and studies, the U.S. Federal and Drug Administration’s (FDA), Adverse Event Reporting System (FAERS) included numerous patient reports and reports from healthcare providers linking Dupixent (dupilumab) to cancer, specifically to multiple types of T-cell lymphoma. FAERS is a vital database that regulators and researchers use to recognize potential drug risks requiring further investigation.
- Reports Confirm Clinical Research: As you will note by visiting FAERS from the button below, the current dashboard shows close to 300 reports of T-cell lymphoma cases among Dupixent patients, which includes confirmed reports of cutaneous T-cell lymphoma (CTCL) and other related and serious conditions. These patient and healthcare reports to the FDA continue to fuel concerns that was addressed in clinical studies, strengthening the need for doctors to closely monitoring patients taking Dupixent.
- The database shows the following type of cases have been reported by patients taking Dupixent or reported by healthcare providers:
-
- Cutaneous T-Cell Lymphoma
- Adult T-Cell Lymphoma/Leukemia
- T-Cell Lymphoma (general)
- CTCL, Stage IV
- CTCL, Stage III
- Angioimmunoblastic T-Cell Lymphoma
- CTCL, Stage I
- Recurrent T-Cell Lymphoma
- Lymphoma (unspecified)
- Anaplastic Large Cell Lymphoma (T- and null-cell types)
- Unclassifiable T-Cell Lymphoma
Volume of Reports: The vast volume of these reports only provides further evidence that Dupixent may be contributing to serious cancer risks in certain patients.
Key Warning Signs for Dupixent and Cancer
Severe Eczema Patients Be Vigilant: For individuals using Dupixent for severe eczema, the diagnostic challenge is compounded because the drug’s anti-inflammatory action may temporarily mask or alter the appearance of early CTCL symptoms.
- Be Aware of Warning Signs Early: Warning signs that may differentiate CTCL from typical eczema in Dupixent users include:
-
- Failure to respond to treatment: Rashes or lesions that persist, worsen, or spread despite ongoing Dupixent use should raise suspicion of an underlying condition.
-
- Progression to plaques and tumors: The development of thicker, raised lesions (plaques) or lumps/nodules (tumors) that can ulcerate is a sign of advancing CTCL not typically seen in standard eczema.
-
- Development of systemic symptoms: Advanced CTCL can lead to symptoms not associated with eczema, such as persistently swollen lymph nodes (in the neck, armpits, or groin), unexplained fatigue, or weight loss.
-
- Sudden acceleration of symptoms: In some case reports, patients experienced a rapid worsening of skin changes shortly after starting Dupixent, suggesting the drug may accelerate the progression of an undetected lymphoma.
Skin Changes and Seeking Immediate Medical Help: If you notice persistent or unusual skin changes while on Dupixent, it is crucial to seek a medical evaluation, including a skin biopsy reviewed by a specialist familiar with cutaneous lymphomas
Who is Eligible for a Dupixent Cancer Lawsuit?
Dupixent Cancer Lawsuit: You may be eligible if you:
- Used Dupixent (dupilumab) as prescribed
- Were later diagnosed with T-Cell Lymphoma, especially Cutaneous T-Cell Lymphoma
- Experienced serious Dupixent side effects or worsening symptoms
- Are within your state’s statute of limitations
Compensation in a Dupixent Cancer Lawsuit
If you are eligible for a Dupixent Cancer Lawsuit, a successful plaintiff is entitled to compensatory damages which would include compensation for things such as:
- past and future medical expenses;
- pain and suffering including emotional distress; and
- lost wages and the reduction in your ability to earn an income.
If your case proceeds to trial it is also possible the court could impose punitive damages, intended to punish the defendant for their actions. Contact Nashville Dupixent Cancer Lawyer Timothy L. Miles who can tell you if you are eligible for a Dupixent Cancer Lawsuit and can explain more about the type of damages you are entitled to receive. (855) 846–6529 or [email protected].
If I Was Diagnosed with Dupixent and Cancer, How Do I Get Started?
- Get a Free Case Evaluation: If you or a loved on developed Dupixent and Cancer after taking Dupixent, the most important thing to do now is get a free case evaluation from a Dupixent Cancer Lawyer to see if you qualify for a Dupixent Cancer Lawsuit. These are not typical cases any lawyer can litigate. Contact Dupixent Cancer Lawyer Timothy L. Miles who can tell you if you are eligible for a Dupixent Cancer Lawsuit and can explain more about what will happen next. (855) 846–6529 or [email protected].
- Medical Records Review: The earlier your records are reviewed, the stronger the foundation becomes, especially in cases where the biopsy history is limited or where the initial diagnosis was “eczema” that simply never responded the way it should have. A lawyer experienced in drug litigation can help secure the complete medical file, obtain an independent pathology review if necessary, and establish a clear timeline that courts and juries can follow.
- Time Is of the Essence: If you have a valid case, then it is vital to preserve your rights under the statute of limitations in your state. These deadlines are different in different states, but it normally starts running from the time of diagnosis or from the point when a reasonable person should have realized the connection between the diagnosis and the drug. Time is of the essence so give Dupixent Cancer Lawyer Timothy L. Miles a call today.
Contingency Fee Agreements: No Cost to Hire a Lawyer
- No Fee: It does not cost anything to hire a lawyer if you are eligible for a Dupixent Cancer Lawsuit. We take all cases on a contingency basis which means we do not get paid unless we win or settle your case.
- Talk with a Lawyer Free of Charge: A lawyer can explain the process of a Dupixent Cancer Lawsuit and answer any questions you may have free of charge. The call is free and so is the fee unless we will or settle your case, so call Nashville Dupixent Cancer Lawsuit Timothy L. Miles today to see if you may be entitled to significant compensation.
Frequently Asked Questions about Dupixent Cancer Lawsuit
What is the link between Dupixent and cancer, and why are there Dupixent Cancer Lawsuits?
Recent concerns have arisen about a potential link between Dupixent and cancer, prompting individuals to file Dupixent Cancer Lawsuits. While research is ongoing, some patients have alleged that their use of Dupixent led to cancer diagnoses or increased risk of developing certain types of cancer. If you have questions about the connection between Dupixent and cancer or are considering legal action, consulting a Nashville Dupixent Cancer Lawyer can help clarify your options.
Who is eligible for a Dupixent Lawsuit or may qualify for a Dupixent Cancer Lawsuit?
Individuals who have used Dupixent and subsequently developed cancer or suffered severe side effects may be eligible for a Dupixent Lawsuit. Eligibility often depends on factors such as duration of use, type of cancer diagnosed, medical history, and whether adequate warnings were provided by the manufacturer. A knowledgeable Nashville Dupixent Cancer Lawyer can review your case details to determine if you qualify for a Dupixent Lawsuit.
What side effects of Dupixent should patients be aware of when considering a Dupixent Lawsuit?
Patients using Dupixent should be informed about possible side effects, which may include injection site reactions, eye problems, allergic reactions, and—according to recent lawsuits—a possible increased risk of developing cancer. If you have experienced serious adverse effects after taking Dupixent, it’s important to document your symptoms and speak with a Nashville Dupixent Cancer Lawyer about your legal rights under current Dupixent Lawsuits.
What kind of compensation might be available in a Dupixent Lawsuit?
Compensation in a Dupixent Lawsuit can cover medical expenses related to treating cancer or other side effects, lost wages due to inability to work, pain and suffering, and possibly punitive damages if negligence by the manufacturer is proven. A skilled Nashville Dupixent Cancer Lawyer can assess your case and help pursue the maximum compensation available through individual or consolidated Dupixent Cancer Lawsuits.
How can I start the process with a Nashville Dupixent Cancer Lawyer regarding my eligibility for a lawsuit?
If you believe you have been harmed by using Dupixent—especially if you’ve developed cancer—you can begin by contacting an experienced Nashville Dupixent Cancer Lawyer for a free consultation. They will evaluate whether your circumstances fit the criteria for existing or new Dupixent Lawsuits and guide you through gathering evidence, filing necessary paperwork, and pursuing justice through a potential Dupixent Cancer Lawsuit.
Contact Nashville Dupixent Cancer Lawyer Timothy L. Miles Today About a Dupixent Cancer Lawsuit
If you believe you qualify for a Dupixent Cancer Lawsuit, contact Nashville Dupixent Cancer Lawyer Timothy L. Miles today for a free case evaluation to see if you are eligible for a Dupixent Cancer Lawsuit and possible entitled to substantial compensation. 855/846-6529 or via e-mail at [email protected]. (24/7/365).
Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: [email protected]
Website: www.classactionlawyertn.com